The combination of nivolumab and cabozantinib has been found to improve overall survival in patients with advanced renal cell carcinoma compared to the previous standard treatment of sunitinib. This was shown in the phase 3 CheckMate 9ER trial. While this combination is not the only one to show a survival advantage over sunitinib in a phase 3 trial, the results indicate its effectiveness in treating advanced RCC. Nivolumab and cabozantinib have the potential to be a more successful treatment option for patients with this type of cancer.
Source link
ICI Provides Survival Benefit in Renal Cell Carcinoma
